

Kidney Disease Focused Drug Discovery and Early Pre-Clinical Development

Our client is a Japan-based global pharmaceutical company that has a passion for contributing to human health through innovative drug discovery, driven by state-of-the-art technologies in nephrology, one of its core therapeutic areas.

Our client is interested in **early-stage drug discovery and preclinical research to identify next generation small molecule and biologics (including antibody approaches and protein therapeutics) approaches to treat kidney diseases with high unmet needs.**



Approaches of Interest

1. Primary Interest: Potential New Drug Substance

A new drug substance, such as a small molecule, antibody, recombinant protein, and other potential modality, that physiologically/pathophysiologically has a novel impact on kidney, regardless by direct or indirect action.

- Competitive edge over current standards of care and emerging/existing competitive drugs in the target indications
- Potential effects on patient populations resistant to conventional therapies

2. Secondary Interest: Novel Druggable Target

A novel druggable target molecule and/or biological modes of action with a clear linkage to human diseases, including rare disease indications.

- Modulation of molecules thought to be difficult to target with conventional drugs

Diseases of Interest

Chronic Kidney Disease, Acute Kidney Disease, Rare/genetic kidney disease and Kidney-related disease with high unmet medical needs.

Stage of Development

Our client is interested in research at the early drug discovery stage through late preclinical stage. Its highest interest is in research opportunities with *in vivo* validation data already obtained using the test/candidate compound.






Out of Scope

Renal cancer, dialysis complication, renal transplantation, cell therapy and exosome therapy, drug repurposing.

Incentives for Academics & Submission Information

- The company is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project funding, and research collaboration.
- Submission of one page, 200-300 word briefs are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **22nd November 2021 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

